Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Pediatric Transplants

Consolidation of first-line therapy with busulphan and melphalan, and autologous stem cell rescue in children with Ewing’s sarcoma

Bone Marrow Transplantation volume 47, pages 1530–1534 (2012)Cite this article

Subjects

Abstract

According to the published report on current practice of hematopoietic SCT in Europe, high-dose therapy (HDT) with autologous stem cell support is a standard of care in paediatric patients with high risk (HR) or relapsed Ewing′s sarcoma (ES). Randomized trials, however, have not confirmed the value of this procedure yet. In this retrospective analysis we intended to evaluate the role of HDT as a consolidation therapy in first remission of ES. A total of 102 patients were included in the analysis and divided according to the following risk factors: metastatic disease at presentation, feasibility of surgery and histological response after induction. Forty-one patients were classified as standard risk (SR) patients, while the remaining 61 children, with at least one risk factor, were classified as HR patients. HR group patients were non-randomized and qualified according to the decision of the local clinician to give a conventional consolidation (CC) or to perform high-dose chemotherapy and radiotherapy in selected patients. Twenty-six children were given CC while 35 patients were treated with HDT. The HDT consisted of oral BU 4 mg/kg p.o. in divided doses daily for 4 days (total dose 16 mg/kg) followed by melphalan 140 mg/m2 i.v. on day −2. Probability of relapse-free survival (RFS) in median observation time was significantly worse in HR patients who were given CC therapy as compared with children with HR features receiving high-dose chemotherapy (0.27 vs 0.66 (P=0.008); OS 0.31 vs 0.71 (P=0.007), respectively). Patients from the SR group had a probability of RFS of 0.72 and OS of 0.75, and the difference between SR and HR patients after HDT was NS (P=0.37). Our observation confirms that the consolidation of the first-line treatment with BU and melphalan improves the outcome in ES patients with HR features.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Esiashvili N, Goodman M, Marcus RB . Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades. J Pediatr Hematol Oncol 2008; 30: 425–430.

    Article  Google Scholar 

  2. Ljungman P, Bregni M, Brune M, Cornelissen J, de Witte T, Dini G et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant 2010; 45: 219–234.

    Article  CAS  Google Scholar 

  3. Atra A, Whelan JS, Calvagna V, Shankar AG, Ashley S, Shepherd V et al. High dose busulfan/melfalan with autologus stem cell rescue in Ewing′s sarcoma. Bone Marrow Transplant 1997; 20: 843–846.

    Article  CAS  Google Scholar 

  4. Madero L, Munoz A, Sanchez de Toledo J, Dıaz MA, Maldonado MS, Ortega JJ et al. Megatherapy in children with high-risk Ewing’s sarcoma in first complete remission. Bone Marrow Transplant 1998; 21: 795–799.

    Article  CAS  Google Scholar 

  5. Oberlin O, Rey A, Desfachelles AS, Philip T, Plantaz D, Schmitt C et al. Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors: a study by the Société Française des Cancers de l'Enfant. J Clin Oncol 2006; 24: 3997–4002.

    Article  CAS  Google Scholar 

  6. Al-Faris N, Al Harbi T, Goia C, Pappo A, Doyle J, Gassas A . Does consolidation with autologous stem cell transplantation improve the outcome of children with metastatic or relapsed Ewing sarcoma? Pediatr Blood Cancer 2007; 49: 190–195.

    Article  Google Scholar 

  7. Gardner SL, Carreras J, Bourdeau C, Camitta BM, Adams RH, Chen AR et al. Myeloablative therapy with autologus stem cell rescue for patients with Ewing sarcoma. Bone Marrow Transplant 2008; 41: 867–872.

    Article  CAS  Google Scholar 

  8. Diaz MA, Lassaletta A, Perez A, Sevilla J, Madero L, Gonzalez-Vicent M . High-Dose Busulfanand Melphalan as Conditioning Regimen for Autologous Peripheral Blood Progenitor Cell Transplantation in High-Risk Ewing Sarcoma Patients: a Long-Term Follow-up Single-Center Study. Pediatr Hematol Oncol 2010; 27: 272–282.

    Article  CAS  Google Scholar 

  9. Ladenstein R, Potschger U, Le Deley MC, Whelan J, Paulussen M, Oberlin O et al. Primary Disseminated Ewing Sarcoma: Results of the Euro-EWING 99 Trial. J Clin Oncol 2010; 28: 3284–3291.

    Article  CAS  Google Scholar 

  10. Ferrari S, Sundby Hall K, Luksch R, Tienghi A, Wiebe T, Fagioli F et al. Nonmetastatic Ewing family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol. Ann Oncol 2011; 22: 1221–1227.

    Article  CAS  Google Scholar 

  11. Rosenthal J, Bolotin E, Shakhnovits M, Pawlowska A, Falk P, Qian D et al. High-dose therapy with hematopoietic stem cell rescue in patients with poor prognosis Ewing family tumors. Bone Marrow Transplant 2008; 42: 311–318.

    Article  CAS  Google Scholar 

  12. Hawkins D, Barnett T, Bensinger W, Gooley T, Sanders J . Busulfan, melphalan, and thiotepa with or without total marrow irradiation with hematopoietic stem cell rescue for poor-risk Ewing-Sarcoma-Family tumors. Med Pediatr Oncol 2000; 34: 328–337.

    Article  CAS  Google Scholar 

  13. Burdach S, Thiel U, Schoniger M, Haase R, Wawer A, Nathrath M et al. Total body MRI-governed involved compartment irradiation combined with high-dose chemotherapy and stem cell rescue improves long-term survival in Ewing tumor patients with multiple primary bone metastases. Bone Marrow Transplant 2010; 45: 483–489.

    Article  CAS  Google Scholar 

  14. Lucas KG, Schwartz C, Kaplan J . Allogeneic stem cell transplantation in a patient with relapsed Ewing sarcoma. Pediatr Blood Cancer 2008; 51: 142–144.

    Article  Google Scholar 

  15. Thiel U, Wawer A, Wolf P, Badoglio M, Santucci A, Klingebiel T et al. Solid Tumor Working Party (STWP) and the Pediatric Disease Working Party (PDWP) of the European Group for Blood and Marrow Transplantation (EBMT); Asia Pacific Blood and Marrow Transplantation (APBMT); Pediatric Registry for Stem Cell Transplantations (PRST); MetaEICESS Study Group. No improvement of survival with reduced- versus high-intensity conditioning for allogeneic stem cell transplants in Ewing tumor patients. Ann Oncol 2011; 22: 1614–1621.

    Article  CAS  Google Scholar 

  16. Mackall CL, Rhee EH, Read EJ, Khuu HM, Leitman SF, Bernstein D et al. A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas. Clin Cancer Res 2008; 14: 4850–4858.

    Article  CAS  Google Scholar 

  17. Juergens H, Daw NC, Geoerger B, Ferrari S, Villarroel M, Aerts I et al. Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J Clin Oncol 2011; 29: 4534–4540.

    Article  CAS  Google Scholar 

  18. Delattre O, Zucman J, Melot T, Garau XS, Zucker JM, Lenoir GM et al. The Ewing family of tumors–a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N Engl J Med 1994; 331: 294–299.

    Article  CAS  Google Scholar 

  19. Le Deley MC, Delattre O, Schaefer KL, Burchill SA, Koehler G, Hogendoorn PC et al. Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial. J Clin Oncol 2010; 28: 1982–1988.

    Article  CAS  Google Scholar 

  20. van Doorninck JA, Ji L, Schaub B, Shimada H, Wing MR, Krailo MD et al. Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol 2010; 28: 1989–1994.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatric Hematology, Oncology and Transplantology, Medical University of Lublin, Lublin, Poland

    K Drabko, M Choma, B Wojcik, A Zaucha-Prazmo & J Kowalczyk

  2. Department of Pediatrics and Adolescent Oncological Surgery, Institute of Mother and Child, Warsaw, Poland

    A Raciborska, K Bilska & W Wozniak

  3. Department of Pediatric Hematology and Oncology, Nicolaus Copernicus University, Bydgoszcz, Poland

    J Styczynski & M Wysocki

  4. Department of Pediatric Hematology, Oncology and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland

    M Ussowicz, E Gorczynska & A Chybicka

  5. Transplantation Centre, University Children′s Hospital, Cracow, Poland

    S Skoczen & J Gozdzik

Authors
  1. K Drabko
    View author publications

    Search author on:PubMed Google Scholar

  2. A Raciborska
    View author publications

    Search author on:PubMed Google Scholar

  3. K Bilska
    View author publications

    Search author on:PubMed Google Scholar

  4. J Styczynski
    View author publications

    Search author on:PubMed Google Scholar

  5. M Ussowicz
    View author publications

    Search author on:PubMed Google Scholar

  6. M Choma
    View author publications

    Search author on:PubMed Google Scholar

  7. B Wojcik
    View author publications

    Search author on:PubMed Google Scholar

  8. A Zaucha-Prazmo
    View author publications

    Search author on:PubMed Google Scholar

  9. E Gorczynska
    View author publications

    Search author on:PubMed Google Scholar

  10. S Skoczen
    View author publications

    Search author on:PubMed Google Scholar

  11. W Wozniak
    View author publications

    Search author on:PubMed Google Scholar

  12. A Chybicka
    View author publications

    Search author on:PubMed Google Scholar

  13. M Wysocki
    View author publications

    Search author on:PubMed Google Scholar

  14. J Gozdzik
    View author publications

    Search author on:PubMed Google Scholar

  15. J Kowalczyk
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to K Drabko.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Drabko, K., Raciborska, A., Bilska, K. et al. Consolidation of first-line therapy with busulphan and melphalan, and autologous stem cell rescue in children with Ewing’s sarcoma. Bone Marrow Transplant 47, 1530–1534 (2012). https://doi.org/10.1038/bmt.2012.78

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/bmt.2012.78

Keywords

This article is cited by

Search

Advanced search

Quick links